Participant | Age | Gender | The duration of treatment (months) | Molecularly targeted drug |
A | 60’s | F | 8 | Gefitinib |
B | 80’s | F | 17 | Erlotinib (2nd line) |
C | 80’s | F | 1 | Gefitinib |
D | 70’s | M | 15 | Erlotinib |
E | 60’s | M | 16 | Afatinib |
F | 70’s | F | 10 | Osimertinib (2nd line) |
G | 70’s | F | 39 | Gefitinib |
H | 80’s | F | 1 | Gefitinib |
I | 70’s | F | 2 | Gefitinib |
J | 70’s | M | 2 | Gefitinib |
K | 60’s | M | 22 | Osimertinib (4th line) |
L | 80’s | M | 8 | Gefitinib |
M | 70’s | M | 29 | Erlotinib (2nd line) |
N | 60’s | F | 3 | Erlotinib |
O | 80’s | M | 7 | Gefitinib |
P | 60’s | M | 31 | Afatinib |
Q | 80’s | F | 13 | Osimertinib (2nd line) |